Cite
HARVARD Citation
Zauderer, M. et al. (2022). EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. Lancet oncology. 23 (6), pp. 758-767. [Online].